170 related articles for article (PubMed ID: 12517816)
1. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.
Karlsson A; Giuriato S; Tang F; Fung-Weier J; Levan G; Felsher DW
Blood; 2003 Apr; 101(7):2797-803. PubMed ID: 12517816
[TBL] [Abstract][Full Text] [Related]
2. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
[TBL] [Abstract][Full Text] [Related]
3. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
4. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.
Choi PS; Li Y; Felsher DW
Proc Natl Acad Sci U S A; 2014 Aug; 111(32):E3316-24. PubMed ID: 25071175
[TBL] [Abstract][Full Text] [Related]
5. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
[TBL] [Abstract][Full Text] [Related]
6. Reversible tumorigenesis by MYC in hematopoietic lineages.
Felsher DW; Bishop JM
Mol Cell; 1999 Aug; 4(2):199-207. PubMed ID: 10488335
[TBL] [Abstract][Full Text] [Related]
7. Biology of the lymphomas: cytogenetics, molecular biology, and virology.
Ambinder RF; Griffin CA
Curr Opin Oncol; 1991 Oct; 3(5):806-12. PubMed ID: 1661167
[TBL] [Abstract][Full Text] [Related]
8. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
Giuriato S; Ryeom S; Fan AC; Bachireddy P; Lynch RC; Rioth MJ; van Riggelen J; Kopelman AM; Passegué E; Tang F; Folkman J; Felsher DW
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16266-71. PubMed ID: 17056717
[TBL] [Abstract][Full Text] [Related]
9. MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia.
Loosveld M; Bonnet M; Gon S; Montpellier B; Quilichini B; Navarro JM; Crouzet T; Goujart MA; Chasson L; Morgado E; Picard C; Hernandez L; Fossat C; Gabert J; Michel G; Nadel B; Payet-Bornet D
Genes Chromosomes Cancer; 2014 Jan; 53(1):52-66. PubMed ID: 24249258
[TBL] [Abstract][Full Text] [Related]
10. A novel tumorigenic human prostate epithelial cell line (M2205): molecular cytogenetic characterization demonstrates C-MYC amplification and jumping translocations.
Jackson-Cook C; Zou Y; Turner K; Astbury C; Ware J
Cancer Genet Cytogenet; 2003 Feb; 141(1):56-64. PubMed ID: 12581899
[TBL] [Abstract][Full Text] [Related]
11. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.
Choi PS; van Riggelen J; Gentles AJ; Bachireddy P; Rakhra K; Adam SJ; Plevritis SK; Felsher DW
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17432-7. PubMed ID: 21969595
[TBL] [Abstract][Full Text] [Related]
12. Double-hit lymphoma demonstrating t(6;14;18)(p25;q32;q21), suggesting two independent dual-hit translocations, MYC/BCL-2 and IRF4/BCL-2.
Tabata R; Yasumizu R; Tabata C; Kojima M
J Clin Exp Hematop; 2013; 53(2):141-50. PubMed ID: 23995111
[TBL] [Abstract][Full Text] [Related]
13. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
[TBL] [Abstract][Full Text] [Related]
14. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
[TBL] [Abstract][Full Text] [Related]
15. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.
Wu CH; van Riggelen J; Yetil A; Fan AC; Bachireddy P; Felsher DW
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13028-33. PubMed ID: 17664422
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inactivation of MYC for the treatment of cancer.
Felsher DW; Bradon N
Drug News Perspect; 2003; 16(6):370-4. PubMed ID: 12973448
[TBL] [Abstract][Full Text] [Related]
17. Neoplastic development in B-lymphocytes.
Potter M
Carcinogenesis; 1990 Jan; 11(1):1-13. PubMed ID: 2403854
[TBL] [Abstract][Full Text] [Related]
18. Murine T lymphomas with retroviral inserts in the chromosomal 15 locus for plasmacytoma variant translocations.
Graham M; Adams JM; Cory S
Nature; 1985 Apr 25-May 1; 314(6013):740-3. PubMed ID: 3990802
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies.
Yu D; Dews M; Park A; Tobias JW; Thomas-Tikhonenko A
Cancer Res; 2005 Jun; 65(12):5454-61. PubMed ID: 15958595
[TBL] [Abstract][Full Text] [Related]
20. Rehabilitation of cancer through oncogene inactivation.
Shachaf CM; Felsher DW
Trends Mol Med; 2005 Jul; 11(7):316-21. PubMed ID: 15955741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
